US · Energy · Oil & Gas Equipment & Services
EPS came in at 0.16 against a street estimate of 0.17 — a miss of 5.9%.
Analysts rate Core Laboratories NV a buy (2 buy, 0 hold, 1 sell out of 3) with an average price target of $15.00.
MIXED Q3 revenue and earnings improved sequentially, but geopolitical disruption pressured international services and margins. Q4 revenue is guided roughly flat, with EPS of $0.12–$0.20. Q3 FY26 U.S. product demand improved, while international services continued facing project delays, sanctions and logistics disruptions. Analysts pressed management on the regional outlook for 2027 spending and U.S. production-enhancement demand. Management emphasized broad international opportunities, improving diagnostics and continued technology adoption. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| Ariel Investments, LLC | 30.67% |
| BlackRock Inc | 16.26% |
| Disciplined Growth Investors Inc | 6.63% |
| Earnest Partners LLC | 6.41% |
| State Street Corp | 4.74% |
| CWA Asset Management Group, LLC | 3.83% |
| Vanguard Capital Management, LLC | 3.47% |
| Dimensional Fund Advisors, Inc. | 3.37% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.01 / share ex-date Nov 9, 2026 · pay Nov 30, 2026 | 2026-11-09 |
| Dividend | $0.01 / share ex-date Aug 10, 2026 · pay Aug 31, 2026 | 2026-08-10 |
| Dividend | $0.01 / share ex-date May 11, 2026 · pay Jun 1, 2026 | 2026-05-11 |
| Dividend | $0.01 / share ex-date Feb 13, 2026 · pay Mar 9, 2026 | 2026-02-13 |
| Dividend | $0.01 / share ex-date Nov 3, 2025 · pay Nov 24, 2025 | 2025-11-03 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Core Laboratories NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.